Comparison of Neuro-navigational Systems for Resection-Control of Brain Tumors
Comparison of Two Neuro-navigational Systems for Resection-control of Intra-axial Brain Tumors. The PoleStarN-20 Intra-operative Magnet Resonance Imager and the Mison SonoWand Intra-operative Ultrasound System
Purpose:
- Improvement of extent of resection by the use of intraoperatively acquired image data sets to navigate.
- Better define the role of different intra-operative imaging modalities, used to update the navigational data set, in aiding the surgeon during resection of intra-axial brain lesions.
- To examine the cost-effectiveness of different intraoperative navigational systems as a function of operative time and Operative time (Surgery including imaging)
There is increasing neuro-oncological evidence that extent of resection might have an impact in particular in low-grade lesions.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Andrew Kanner, MD
- Phone Number: 972-3-6974075
- Email: andrewk@tasmc.health.gov.il
Study Contact Backup
- Name: Carmit Ben Harosh, RN,MA
- Phone Number: 972-3-6974397
- Email: carmitbh@tasmc.health.gov.il
Study Locations
-
-
-
Tel-Aviv, Israel, 64239
- Tel-Aviv Sorasky MC
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must have neuro-radiological evidence of a brain lesion. Eligible are all histological types of brain lesions.
- > 18 years of age.
- Male and female.
- Patient must be a surgical candidate, according to general anesthetic and neurosurgical criteria.
- Patient should be able to undergo MRI.
- Informed consent as per protocol.
Exclusion Criteria:
- Patient unwilling to undergo surgery for resection of brain tumor.
- Patient medically not eligible to undergo craniotomy. (Medical contraindication).
- Patient has a medical contraindication or is unwilling to undergo MRI scanning (pacemaker, other metal device ot parts in head or body,).
- Kidney function compromise (Creatinine values > 1.4 mg/dL).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Intraoperative MR
Use of intraoperative MR during resection of intraaxial tumor, Glioma
|
intraoperative imaging for resection control of intraaxial brain lesions
Other Names:
|
|
Other: Intraoperative Ultrasound
Use of intraoperative ultrasound during resection of intraaxial tumor, Glioma
|
intraoperative imaging for resection control of intraaxial brain lesions
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The primary end point of the study is assessment and comparison of intra-operative Magnet Resonance Imaging and ultrasound to better define its impact on the extent of resection.
Time Frame: 72 hours
|
72 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Secondary end points should identify criteria for selecting the right system for a specific patient (Patient selection), and cost-effectiveness.
Time Frame: 3-6 months
|
3-6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Andrew Kanner, MD, Tel-Aviv Sorasky Medical Center
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Glioma
- Brain Neoplasms
Other Study ID Numbers
Other Study ID Numbers
- TASMC-09-AK-0351
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioma
-
NCT07506239RecruitingPediatric Cancer | Low-grade Glioma | Low Grade Glioma of Brain | Recurrent Low Grade Glioma
-
NCT02208362Active, not recruitingRecurrent Glioblastoma | Recurrent Malignant Glioma | Refractory Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma | Refractory Glioblastoma | Refractory WHO Grade II Glioma | Refractory WHO Grade III Glioma
-
NCT05555550RecruitingGlioma | Low-grade Glioma | Glioma, Malignant | Low Grade Glioma of Brain | Glioma Intracranial
-
NCT06964737RecruitingWHO Grade 3 Glioma | Recurrent Malignant Glioma | WHO Grade 2 Glioma | Recurrent WHO Grade 3 Glioma | Recurrent WHO Grade 4 Glioma | WHO Grade 4 Glioma
-
NCT05553041RecruitingGlioma | High Grade Glioma | Glioma, Malignant | Diffuse Glioma | Glioma Intracranial
-
NCT02525692TerminatedGlioblastoma | Diffuse Midline Glioma | H3 K27M Glioma | Thalamic Glioma | Infratentorial Glioma | Basal Ganglia Glioma
-
NCT03389230Active, not recruitingGlioblastoma | Malignant Glioma | WHO Grade III Glioma | Recurrent Glioma | Refractory Glioma
-
NCT03749187Active, not recruitingGlioblastoma | Malignant Glioma | Recurrent Glioblastoma | Recurrent WHO Grade III Glioma | WHO Grade III Glioma | IDH2 Gene Mutation | IDH1 Gene Mutation | Low Grade Glioma | Recurrent WHO Grade II Glioma | WHO Grade II Glioma
-
NCT07389278Not yet recruitingGlioblastoma | Diffuse Midline Glioma, H3 K27M-Mutant | High-grade Glioma | High-Grade Glioma (WHO III-IV) | Diffuse Hemispheric Glioma, H3G34 Mutant
-
NCT03952598SuspendedGlioma | High Grade Glioma | Malignant Glioma | Gliomas | Low Grade Glioma
Clinical Trials on Intraoperative MR (PoleStar N-20, Medtronics)
-
NCT05753306RecruitingGastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Metastatic Malignant Neoplasm in the Peritoneum